EP1509614A4 - Map-kinase inhibitors as regulators of tumor-associated antigen expression - Google Patents

Map-kinase inhibitors as regulators of tumor-associated antigen expression

Info

Publication number
EP1509614A4
EP1509614A4 EP03717900A EP03717900A EP1509614A4 EP 1509614 A4 EP1509614 A4 EP 1509614A4 EP 03717900 A EP03717900 A EP 03717900A EP 03717900 A EP03717900 A EP 03717900A EP 1509614 A4 EP1509614 A4 EP 1509614A4
Authority
EP
European Patent Office
Prior art keywords
regulators
tumor
map
kinase inhibitors
associated antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03717900A
Other languages
German (de)
French (fr)
Other versions
EP1509614A1 (en
Inventor
James T Kurnick
Paul J Durda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1509614A1 publication Critical patent/EP1509614A1/en
Publication of EP1509614A4 publication Critical patent/EP1509614A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03717900A 2002-02-15 2003-02-18 Map-kinase inhibitors as regulators of tumor-associated antigen expression Withdrawn EP1509614A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35758602P 2002-02-15 2002-02-15
US357586P 2002-02-15
PCT/US2003/004786 WO2004087941A1 (en) 2002-02-15 2003-02-18 Map-kinase inhibitors as regulators of tumor-associated antigen expression

Publications (2)

Publication Number Publication Date
EP1509614A1 EP1509614A1 (en) 2005-03-02
EP1509614A4 true EP1509614A4 (en) 2007-09-12

Family

ID=33130319

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03717900A Withdrawn EP1509614A4 (en) 2002-02-15 2003-02-18 Map-kinase inhibitors as regulators of tumor-associated antigen expression

Country Status (4)

Country Link
EP (1) EP1509614A4 (en)
AU (1) AU2003222221A1 (en)
CA (1) CA2475206A1 (en)
WO (1) WO2004087941A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001155A (en) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network.
RU2009114745A (en) * 2006-09-19 2010-10-27 Новартис АГ (CH) BIOMARKERS INTENDED FOR IDENTIFICATION OF DIRECTED MODULATION, EFFICIENCY OF RAF INHIBITORS, APPLICATIONS FOR THE DIAGNOSTIC AND / OR FORECASTING
WO2009069668A1 (en) * 2007-11-28 2009-06-04 National University Corporation Nagoya University Agent for increasing the expression of malignant melanoma antigen, and use thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2011156970A1 (en) * 2010-06-18 2011-12-22 Xu Zhiheng Uses of mtea in diagnosis and treatment of malignant tumor
CN103403187A (en) * 2011-01-18 2013-11-20 艾沃锐斯特基因有限公司 Prognostic signature for colorectal cancer recurrence
WO2013001372A2 (en) * 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
CN102274513B (en) * 2011-07-06 2013-02-20 南开大学 Tumor growth inhibited by ERK1/2 inhibitor through stimulating expression of macrophage interferon gamma
EP2971045B1 (en) 2013-03-13 2019-06-19 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
WO2016168264A1 (en) * 2015-04-13 2016-10-20 Kiromic, Llc Methods and compositions for treating cancer with dendritic cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017952A2 (en) * 2000-09-01 2002-03-07 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002017952A2 (en) * 2000-09-01 2002-03-07 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KONO MICHIHIRO ET AL: "Role of the mitogen-activated protein kinase signaling pathway in the regulation of human melanocytic antigen expression.", MOLECULAR CANCER RESEARCH : MCR OCT 2006, vol. 4, no. 10, October 2006 (2006-10-01), pages 779 - 792, XP002433088, ISSN: 1541-7786 *
KOO H-M ET AL: "Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 5, 5 March 2002 (2002-03-05), pages 3052 - 3057, XP002225753, ISSN: 0027-8424 *
KURNICK J T ET AL: "A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 AUG 2001, vol. 167, no. 3, 1 August 2001 (2001-08-01), pages 1204 - 1211, XP002433087, ISSN: 0022-1767 *
See also references of WO2004087941A1 *

Also Published As

Publication number Publication date
WO2004087941A1 (en) 2004-10-14
EP1509614A1 (en) 2005-03-02
CA2475206A1 (en) 2003-08-15
AU2003222221A1 (en) 2004-10-25

Similar Documents

Publication Publication Date Title
HK1077762A1 (en) INHIBITORS OF TFGβ
GB2432159B (en) Intermediates for manufacturing peripherally-selective inhibitors of dopamine-beta-hydroxylase
HK1080069A1 (en) Nitrooxyderivatives of cyclooxygenase-2 inhibitors
HK1072545A1 (en) Novel inhibitors of kinases
PL377825A1 (en) Diaminotriazoles useful as inhibitors of protein kinases
IL205511A0 (en) Methods and compositions for the production of monoclonal antibodies
SI1587542T1 (en) Use of anti-cd100 antibodies
IL223579A0 (en) Synthesis of amines and intermediates for the synthesis thereof
TWI349525B (en) Immunization of plants against bacterioses
EP1509226A4 (en) Small molecule inhibitors of her2 expression
AU2003217105A8 (en) Novel of cytokine inhibitors
EP1509614A4 (en) Map-kinase inhibitors as regulators of tumor-associated antigen expression
TW200508233A (en) Chk-1 inhibitors
PL371217A1 (en) Inhibitors of integrin alphavbeta6
AU2003205106A1 (en) Pace-a microspheres for delivery of antigens
AU2003293004A1 (en) Identification of agonistic autoantibodies
GB0201504D0 (en) Method of payment
AU2003295638A8 (en) Novel inhibitors of beta-lactamase
PL374342A1 (en) 1-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the prepartion thereof
PL373523A1 (en) Indol-2-ones as selective inhibitors of cyclooxygenase-2
AU2003250151A8 (en) Method for the synthesis of anthracycline-peptide conjugates
AU2003258941A8 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
GB0206415D0 (en) Deracemisation of amines
MXPA02004180A (en) Synthesis methods of hydroxy-alkyl-phenyl amides.
AU2003276825A8 (en) Method of immunotherapy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040831

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

A4 Supplementary search report drawn up and despatched

Effective date: 20070810

17Q First examination report despatched

Effective date: 20071112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080523